The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Remaining unmet needs in extensive-stage small cell lung cancer
Francesco Grossi, MD, University of Insubria, Varese, Italy, comments on the limitations of immunotherapy in small cell lung cancer (SCLC), highlighting that despite its potential, the treatment duration is often limited, resulting in a meagre five-year survival rate. Additionally, the lack of a specific target for SCLC, unlike non-small cell lung cancer, makes it challenging to select patients and develop targeted therapies. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
What is the problem with immunotherapy? So the problem is that also with immunotherapy we treat patients unfortunately for a few months. So that’s a problem because we need results similar to non-small cell lung cancer with prolonged survival, with prolonged benefit. And now we hope that there are a small group of patients cured also in small cell lung cancer using immunotherapy...
What is the problem with immunotherapy? So the problem is that also with immunotherapy we treat patients unfortunately for a few months. So that’s a problem because we need results similar to non-small cell lung cancer with prolonged survival, with prolonged benefit. And now we hope that there are a small group of patients cured also in small cell lung cancer using immunotherapy. But at the moment, the results of the prolonged follow-up in these patients is only around 10-12% of patients alive at five years. So in small cell lung cancer, we need to prolong the treatment. And also another problem is that compared to non-small cell lung cancer, and in particular to adenocarcinoma, we don’t have a target. So that’s a problem because similar to non-small cell lung cancer, in particular the adenocarcinoma probably we need some target for better selecting the patients and have target agents also in small cell lung cancer. But at the moment we don’t have a real target to consider for our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
